PrintThe Burrill Report
The Burrill Report (April 7, 2014): A Growing Tension Between Innovation and Price (.MP3,20.7 Mb)
Gilead Sciences breakthrough hepatitis C drug Sovaldi has changed the treatment and prognosis of the disease, but it’s also fueling a broader debate about the price of innovative therapies. We spoke to Seamus Levine-Wilkinson, group analyst with Decision Resources, about the emerging therapies for hepatitis C, how doctors and payers are viewing them, and what drug companies are learning about pricing breakthrough therapies.
April 03, 2014
http://www.burrillreport.com/article-a_growing_tension_between_innovation_and_price.html
DRUG SPENDING
A Growing Tension Between Innovation and Price
Podcast: April 7, 2014[Please login to post comments]
- Biotech Industry Shatters Fundraising Records in 2014
Ongoing fight over drug pricing overshadows industry in the new year Read More - G. Steven Burrill Issues Annual Predictions for the Biotechnology Industry
Focus to shift from promise to execution in 2015 Read More - Actavis’ $66B Purchase of Allergan Continues Record Year of M&A; Transactions for Life Sciences
Increasingly Competitive Environment for Sought-After Assets Pushes Prices Higher, Says Burrill Media. Read More - AbbVie Terminates Shire Acquisition, But M&A; Activity Remains Brisk
Total life sciences transactions through first 10 months of 2014 reach $253.3 Billion, says Burrill Media Read More - U.S. Government’s Effort to Quell Tax-Driven Acquisitions Could Slow Life Sciences Dealmaking
Nearly half of dollar volume of M&A; activity in 2014 involved inversions, says Burrill Media Read More - Life Sciences M&A; Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Press Release Read More - Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge. Read More - Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment. Read More - Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More - Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014 Read More
